RecruitingPhase 2NCT06032845

Cryoablation Combined with Tislelizumab Plus Lenvatinib in Previously Treated Solid Tumors (CASTLE-11)

A Phase II Study to Evaluate the Efficacy and Safety of Cryoablation Combined with Tislelizumab Plus Lenvatinib in Previously Treated Solid Tumors

Sponsor

Fudan University

Enrollment

25 participants

Start Date

Sep 13, 2023

Study Type

INTERVENTIONAL

Conditions

Solid Tumor, Adult

Summary

The objective of this study is to evaluate the efficacy and safety of cryoablation combined with Tislelizumab plus Lenvatinib for patients with previously treated solid tumors.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a procedure called Cryoablation, a drug called Lenvatinib, and others for people with solid tumor, adult. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.